Abstract:Background and Objectives: The modification of histone acetylation plays a vital role in regulating tumor occurrence and development, but the interaction between histone acetylation modulator genes and the liver hepatocellular carcinoma (LIHC) microenvironment, as well as immunotherapy, has not been investigated. Materials and Methods: Analysis of all statistical data was carried out using R software (Version 4.2.0) and the online tool Sangerbox. Comprehensive bioinformatics analysis, including signature construction and validation, functional analyses, immune and genomic features analyses, and immunotherapy prediction analyses, were performed to explore the prognostic and therapeutic role of histone acetylation modulator genes in LIHC development and progression. Results: The LIHC cohort from The Cancer Genome Atlas (TCGA) database was selected as the training cohort; the GSE76427 cohort from the Gene Expression Omnibus (GEO) database and the LIRI-JP cohort from the International Cancer Genome Consortium (ICGC) database were selected as the validation cohorts. The histone acetylation modulator gene-based prognostic signature was constructed and validated successfully. Immune infiltration analysis showed that most immune cells and immune functions were enriched in patients with high histone acetylation risk scores (HARS). Additionally, high levels of checkpoint inhibitors (ICIs) and human leukocyte antigens (HLAs) were also observed in high HARS patients. Meanwhile, TIDE algorithm analysis was conducted to explore the relationship between HARS and immunotherapy response, and submap algorithm analysis was used for the verification of the results, from which we found that high HAPS patients were more likely to respond to immunotherapy. Conclusions: Our findings revealed that the histone acetylation modulator genes, particularly for KAT21, SIRT6, and HAT1, may have the potential to function as a new prognostic marker and therapeutic target for LIHC.

HAT1: Landscape of Biological Function and Role in Cancer

The Role Of Histone Acetyltransferases In Normal And Malignant Hematopoiesis

Characterization of Histone Deacetylase Mechanisms in Cancer Development

Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.

The Structure and Function of Histone Deacetylases: the Target for Anti-cancer Therapy

Acetyl-CoA Regulates Lipid Metabolism and Histone Acetylation Modification in Cancer

The emerging roles of HDACs and their therapeutic implications in cancer

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy

The role of protein acetylation in carcinogenesis and targeted drug discovery

Systematic Analysis of Histone Acetylation Regulators Across Human Cancers.

Role of Histone Acetylation Modification in Posttranscriptional Gene Expression

Histone acetyltransferase 1 is a succinyltransferase for histones and non‐histones and promotes tumorigenesis

Histone Demethylase Lysine Demethylase 5B in Development and Cancer

HDAC7: a promising target in cancer

Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design

Acetylation of Histone H3 in Cancer Progression and Prognosis

Histone deacetylases and cancer: causes and therapies

Histone deacetylase 6 in cancer

The Prognostic and Therapeutic Role of Histone Acetylation Modification in LIHC Development and Progression

Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer

Genetic and Molecular Characterization Revealed the Prognosis Efficiency of Histone Acetylation in Pan-Digestive Cancers